Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.
Lorenzo PiemontiBart KeymeulenPieter GillardThomas LinnEmanuele BosiLudger RosePozzilli PaoloFrancesco GiorginoEfisio CossuLuisa DaffonchioGiovanni GoisisPier Adelchi RuffiniAnna Rita MauriziFlavio MantelliMarcello AllegrettiPublished in: Diabetes, obesity & metabolism (2022)
In newly diagnosed patients with type 1 diabetes, short-term LDX treatment had no appreciable effect on preserving residual beta cell function.